Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Cell Genesys22 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Myeloma

Interventions

Therapeutic Cellular Vaccine, GM-CSF ProducingBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * De novo multiple myeloma * ECOG 0-2 * No serious co-morbid illnesses and adequate organ function * \> 4 weeks from systemic steroids Exclusion Criteria: * No existing secondary malignancies and no history of secondary malignancies in the past 5 years * No active autoimmune disease

Locations (1)

Johns Hopkins University

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Multiple myeloma

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.